{"id":77656,"date":"2024-03-12T16:44:11","date_gmt":"2024-03-12T21:44:11","guid":{"rendered":"https:\/\/equitynewsreport.com\/ge-healthcare-announces-secondary-offering-of-13-million-shares\/"},"modified":"2024-03-12T16:44:11","modified_gmt":"2024-03-12T21:44:11","slug":"ge-healthcare-announces-secondary-offering-of-13-million-shares","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/ge-healthcare-announces-secondary-offering-of-13-million-shares\/","title":{"rendered":"GE HealthCare announces secondary offering of 13 million shares"},"content":{"rendered":"
\n
\n\"GE
\n\u00a9 Reuters. <\/span>
\n<\/i>\n<\/div>\n

CHICAGO – GE HealthCare (NASDAQ:) Technologies Inc. (NASDAQ:GEHC), a prominent player in the medical technology and diagnostics field, has initiated a secondary public offering of 13 million shares of its common stock. Notably, the company itself will not be selling any shares nor receiving proceeds from this transaction.<\/p>\n

Before the offering’s close, General Electric <\/span><\/span> Company (NYSE:) is expected to engage in a debt-for-equity swap with Morgan Stanley <\/span><\/span> Bank, N.A., the affiliate of Morgan Stanley & Co (NYSE:). LLC, which is designated as the selling stockholder. Post this exchange, Morgan Stanley & Co. LLC plans to sell the acquired GE HealthCare shares to the underwriter.<\/p>\n

The underwriter has been granted an option to purchase additional shares, which if exercised, will be settled by March 28, 2024. Morgan Stanley is serving as the sole book-running manager for the offering, proposing to sell the shares on The Nasdaq Stock Market, over-the-counter market, or through negotiated transactions.<\/p>\n

Investors can access the offering documents, which include a prospectus, through the SEC’s EDGAR database or directly from Morgan Stanley & Co. LLC. It’s important to note that this press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in any state or jurisdiction where such an offer would be unlawful.<\/p>\n

GE HealthCare, with over a century of service to the healthcare sector, aims to enhance the efficiency of hospitals and the effectiveness of clinicians through its integrated solutions and services. The company, which operates a $19.6 billion business with 51,000 employees, focuses on advancing personalized and connected care.<\/p>\n

Investors are cautioned that this release contains forward-looking statements that involve risks and uncertainties, including those related to the offering’s size, timing, and results. These statements are based on current management expectations and are subject to factors that may lead to actual results differing materially.<\/p>\n

These factors are detailed in the company’s filings with the SEC, including a registration statement filed on February 15, 2024.<\/p>\n

This news article is based on a press release statement from GE HealthCare Technologies Inc.<\/p>\n

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. CHICAGO – GE HealthCare (NASDAQ:) Technologies Inc. (NASDAQ:GEHC), a prominent player in the medical technology and diagnostics field, has initiated a secondary public offering of 13 million shares of its common stock. Notably, the company itself will not be selling any shares nor receiving proceeds from this transaction. Before the offering’s close, General Electric Company (NYSE:) is expected to engage in a debt-for-equity swap with Morgan Stanley Bank, N.A., the affiliate of Morgan Stanley & Co (NYSE:). LLC, which is designated as the selling stockholder. Post this exchange, Morgan Stanley & Co. LLC plans to sell the acquired […]<\/p>\n","protected":false},"author":5,"featured_media":77657,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,49,50,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77656"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77656"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77656\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77657"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}